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TransmissionExperimental Ebola virus (EBOV) vaccines have previously been shown to protect animals against a high
dose intramuscular (IM) challenge, which is seen as a stringent challenge model. However, the protective
efﬁcacy against other modes of infection, such as contact with infectious hosts, is unknown. Using a pre-
viously established EBOV transmission animal model, we evaluated the efﬁcacy of an adenovirus-based
EBOV vaccine given to guinea pigs (gps) 4 weeks before direct contact with untreated, infectious animals.
Prior vaccination resulted in robust levels of EBOV-speciﬁc antibodies and conferred complete protection
in gps. These results support the use of vaccines to prevent EBOV transmission between hosts.
Crown Copyright  2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
EBOV is one of the most virulent agents in humans and has
caused sporadic outbreaks primarily localized to the humid,
remote rainforests of sub-Saharan Africa since its discovery in
1976. Initial symptoms of EBOV infection are similar to that of
other more common pathogens, such as fever, nausea, diarrhea
and general malaise before a rapid progression to more speciﬁc
indications including hemorrhage, multi-organ failure and a condi-
tion resembling septic shock (Feldmann and Geisbert, 2011). Death
is the outcome in up to 90% of human cases, occurring between 6
and 10 days after the onset of symptoms (Feldmann and Geisbert,
2011). Clinically approved prophylaxis and post-exposure thera-
peutics currently do not exist for victims of EBOV infection. Due
to the size and scale of the 2014 EBOV outbreak inWest Africa, sev-
eral experimental vaccines are being fast-tracked through clinical
trials in an attempt to protect frontline health workers and limit
the number of new infections. The vaccine candidates currently
being fast-tracked include those based on the vesicular stomatitis
virus (Jones et al., 2005) or the chimpanzee-derived adenovirusserotype 3 platforms (Stanley et al., 2014). Other potential vaccine
candidates slated for upcoming clinical trials include the human
adenovirus serotype 26 or 35 platforms (Geisbert et al., 2011) with
a Modiﬁed vaccinia Ankara (MVA) boost. However, the EBOV chal-
lenge for these vaccine studies in nonhuman primates (NHPs) is
typically an IM infection with a target dose of 1000 plaque forming
units (PFU), which is designed to test whether immunization in
advance is able to protect recipients under stringent challenge con-
ditions, such as an accidental needlestick injury in the laboratory.
While important, this scenario may not be relevant to outbreak sit-
uations, in which transmission between humans likely occurs
through direct contact with infected materials, such as infected
bodily ﬂuids and tissues (Cohen, 2004) in a nosocomial setting or
during traditional burial rituals. As a result, there is an urgent need
to test whether experimental EBOV vaccines are efﬁcacious against
a more common infection route.
A transmission model was recently developed in mucosally-
infected gps, which is one possible route of EBOV infection in ani-
mals (Twenhafel et al., 2015). In this model, an intranasal (IN) chal-
lenge with gp-adapted EBOV (GA-EBOV) resulted in earlier virus
shedding by the infected animal, leading to increased virus trans-
missibility to naïve gps added as cagemates 24 h after infection
(Wong et al., 2014). In addition, a human adenovirus serotype 5
(Ad5)-based vaccine and adjuvant combination (hereafter termed
adjuvanted Ad5-ZGP) was previously shown to confer complete
protection in gps challenged systemically by GA-EBOV at high
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candidate vaccine, our aim is to determine whether immunization
of contact gps 4 weeks before direct exposure to an untreated,
infectious animal is effective at protecting the vaccine recipient
from EBOV transmission. Survival and clinical symptoms, in addi-
tion to viremia and EBOV shedding of contact animals were mon-
itored to conﬁrm vaccine efﬁcacy. Since the speciﬁc antibody
response statistically correlates with survival from EBOV (Wong
et al., 2012), total IgG and neutralizing antibodies were quantiﬁed
before and after challenge from contact animals as an additional
indicator of vaccine-induced protection.
To investigate whether vaccination is able to prevent the sus-
ceptibility of animals to contact EBOV transmission, a group of 3
naïve contact gps were administered IN with 1.2  109 infectious
forming units (IFU) of Ad5-lacZ, and groups of 6 naïve contact
gps were given IN with PBS or 1.0  109 IFU Ad5-ZGP vaccine com-
bined with 2.0  108 IFU Ad5-IFNa adjuvant. Four weeks after vac-
cination, the immunized animals were individually paired-housed
with unvaccinated animals (n = 15) that had been challenged 24 h
previously via the IN route with 10,000  LD50 (220 PFU) of
GA-EBOV (Ebola virus VECTOR/C. porcellus-lab/COD/1976/
Mayinga-GPA, order Mononegavirales, family Filoviridae, species
Zaire ebolavirus; Genbank accession number AF272001.1)
(Connolly et al., 1999). The animals were then monitored over
the next 4 weeks for survival and changes in weight or body tem-
perature. All challenged gps succumbed to disease between 8 and
11 dpi, with a mean time to death of 8.9 ± 1.0 dpi. From contact
gps, PBS-treated control animals resulted in 17% survival, with 5
of 6 animals succumbing to EBOV between 13 and 16 dpi
(Fig. 1A). In contrast, 100% survival was observed in gps given adju-
vanted Ad5-ZGP, with 0 of 6 animals succumbing to disease
(Fig. 1A). Signiﬁcant weight loss or abnormal body temperatures
were not observed in any animals from this vaccination group
(Fig. 1B and C). Ad5-lacZ administration yielded 33% survival, with
2 of 3 gps succumbing to EBOV at 17 and 21 dpi (Fig. 1A). Using the
Logrank Mantel–Cox test, the overall survival between the individ-
ual contact groups was shown to be statistically signiﬁcant
(v2 = 9.555, df = 2, p-value = 0.0084).
Levels of GA-EBOV shedding from contact gps of various immu-
nization groups were measured by blood, oral, nasal and rectalFig. 1. Survival, weight loss, clinical symptoms and GA-EBOV shedding in infected and
EBOV and contact animals were administered PBS, Ad5-lacZ, or adjuvanted Ad5-ZGP via t
monitored for changes in (A) survival, (B) weight loss and (C) body temperature for 4 wee
14 dpi and quantitated for levels of virus shedding by RT-qPCR. RT-qPCR results were eswabs sampled at 14 and 28 dpi using a previously described pro-
tocol (Qiu et al., 2013). Samples were harvested at 14 dpi in order
to compare GA-EBOV viremia and shedding between the various
groups of vaccinated contact gps, and at 28 dpi in order to deter-
mine whether vaccinated survivors still harboured any virus. GA-
EBOV RNA could be detected from oral, nasal and rectal swabs in
only moribund animals given PBS at 105, 104, and 105 GEQ/
mL respectively at 14 dpi, as well as oral secretions of animals
given Ad5-lacZ at 103 GEQ/mL, at 14 dpi. In addition, viremia
was observed in both the PBS and Ad5-lacZ groups, between
105 and 107 GEQ/mL at 14 dpi (Fig. 1D). In contrast, GA-EBOV
RNA was not detected in the blood, as well as oral, nasal and rectal
secretions of gps vaccinated IN with adjuvanted Ad5-ZGP at 14 dpi
(Fig. 1D). GA-EBOV RNA was also not detected in surviving animals
upon termination of the experiment at 28 dpi (data not shown).
To determine whether vaccination resulted in speciﬁc humour-
al immune responses, sera were harvested from all contact animals
before vaccination (26 days before infection of challenge animals),
on the day of challenge (0 dpi), as well as 14 and 28 dpi. IgG anti-
bodies and neutralizing antibodies speciﬁc for the EBOV glycopro-
tein (ZGP) or virion were measured by ELISA and neutralizing
antibody assays, respectively, using a previously established proto-
col (Qiu et al., 2013). The administration of PBS or Ad5-lacZ did not
yield signiﬁcant levels of speciﬁc antibody responses against GA-
EBOV (Fig. 2A and B). Signiﬁcant levels (p < 0.0001) of ZGP-speciﬁc
IgG were observed for gps given adjuvanted Ad5-ZGP, with
endpoint titers of 110,000 ± 33,000, 171,000 ± 66,100 and
192,000 ± 70,100 at 0, 14 and 28 dpi, respectively (Fig. 2A).
Signiﬁcant levels (p < 0.0001) of neutralizing antibodies were also
observed, with gps exhibiting levels of 347 ± 65, 311 ± 92 and
325 ± 129 reciprocal dilutions at 0, 14 and 28 dpi, respectively
(Fig. 2B).
An unprecedented number of local and international medical
personnel in West Africa, Spain and the USA have been infected
in the line of duty during the 2014 EBOV outbreak, despite wearing
full protective gear. These developments have highlighted the
urgent need for a vaccine so that they are able to work safely with-
out putting their lives at risk. Evaluating the effectiveness of prom-
ising medical countermeasures against a more common mode of
EBOV transmission (Dowell et al., 1999) is particularly relevantvaccinated contact gps. Challenge animals were intranasally (IN) infected with GA-
he IN route, 26 days before challenge animals were given GA-EBOV. All animals were
ks after infection. (D) Oral, nasal and rectal swabs were sampled from all animals at
xpressed in GEQ/mL. Error bars represent ± standard deviation.
Fig. 2. Speciﬁc humoural immune responses in treated contact gps following
vaccination and exposure to GA-EBOV infected animals. Guinea pigs were admin-
istered PBS, Ad5-lacZ, or adjuvanted Ad5-ZGP via the IN route and sera were
sampled before vaccination (26 dpi), before challenge (0 dpi), and then at 14 and
28 dpi. Levels of (A) ZGP-speciﬁc IgG antibodies and (B) EBOV-speciﬁc neutralizing
antibodies were analyzed and reported as endpoint titers and reciprocal dilutions,
respectively. Error bars represent ± standard deviation.
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tional burials or the reintroduction of a convalescent patient from
quarantine back into the community. Immunization with Ad5 vac-
cines was performed IN for several reasons: (1) the gp transmission
model used in this study supported GA-EBOV spread from infec-
tious to naïve animals through the airway (Wong et al., 2014);
(2) the relative ease of administration compared to IM injections;
(3) IN administration of Ad5-ZGP had previously been shown to
be efﬁcacious in NHPs, even in the presence of pre-existing immu-
nity toward the same adenovirus serotype (Richardson et al.,
2013); and (4) the ability of mucosal Ad5-ZGP vaccination to
induce durable protection against EBOV challenge in NHPs (Choi
et al., 2014). Although the Ad5-ZGP vaccine is not currently under
consideration for use against the 2014 EBOV outbreak in West
Africa due to concerns over the prevalence of pre-existing immu-
nity against Ad5 among humans in sub-Saharan Africa
(Nwanegbo et al., 2004), these studies indicate that Ad5-based vac-
cines may still be beneﬁcial if advanced into human use to combat
any current or future EBOV outbreaks. Administration with the
control Ad5-lacZ did not prevent GA-EBOV transmission and infec-
tion from contagious animals, as observed by the partial survival of
contact gps in addition to the detection of viral RNA in the blood
and shedding through oral swabs. In contrast, IN administration
of adjuvanted Ad5-ZGP was effective in fully protecting gps from
disease following prolonged exposure to an untreated, moribund
animal. Clinical symptoms were not observed and GA-EBOV RNA
was not detected in the secretions of vaccinated animals despite
prolonged exposure with the contagious animal, suggesting that
vaccination was effective in protecting the otherwise susceptible
hosts from GA-EBOV transmission, and preventing the vaccine
recipients from further propagating EBOV spread.
Although gps do not succumb to infection with wild-type EBOV
and an adapted variant has been utilized in its place, the hallmarksof GA-EBOV infection in gps are quite comparable to wild-type
EBOV infection in NHPs. Taken together, IN vaccination with
Ad5-based EBOV vaccines is an effective countermeasure against
disease caused by EBOV spread between susceptible hosts and
has the potential to prevent the occurrence of new infections dur-
ing an EBOV outbreak.
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